Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 33

recruiting
3 987
countries
28
conditions
2 109

761 trials match your criteria

Back pain

Not recruiting

Study on the Effects of VER-01, Ibuprofen, and Paracetamol for Patients with Chronic Non-Specific Low Back Pain

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dronabinol

Parkinson's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Minzasolmin and Iodine Ioflupane (123I) in Patients with Parkinson's Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)

Dermatitis atopic+1

Not recruiting

Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Glucocorticoids

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran

Hypertriglyceridaemia

Not recruiting

Study on the Effects of Pegozafermin and Simvastatin for Patients with Severe High Triglycerides

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100

Glioblastoma

Not recruiting

Phase 1b Study of CC-90010 with Temozolomide in Adults with Newly Diagnosed Glioblastoma After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Batoprotafib

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.